Click here to load reader
Upload
others
View
0
Download
0
Embed Size (px)
Citation preview
Service Line: Rapid Response Service
Version: 1.0
Publication Date: November 21, 2017
Report Length: 16 Pages
CADTH RAPID RESPONSE REPORT: SUMMARY OF ABSTRACTS
Transcutaneous Bilirubin Measurements in Newborns: Clinical and Cost-Effectiveness, and Guidelines
SUMMARY OF ABSTRACTS Transcutaneous Bilirubin Measurements in Newborns 2
Authors: Calvin Young, Lorna Adcock
Cite As: Transcutaneous bilirubin measurements in newborns: clinical and cost -ef f ectiveness, and guidelines. Ottawa: CADTH; 2017 Nov . (CADTH rapid
response report: summary of abstracts).
Acknowledgments:
Disclaimer: The inf ormation in this document is intended to help Canadian health care decision-makers, health care prof essionals, health sy stems leaders,
and policy -makers make well-inf ormed decisions and thereby improv e the quality of health care serv ices. While pat ients and others may access this document,
the document is made av ailable f or inf ormational purposes only and no representations or warranties are made with respect to its f itness f or any particular
purpose. The inf ormation in this document should not be used as a substitute f or prof essional medical adv ice or as a substitute f or the application of clinical
judgment in respect of the care of a particular patient or other prof essional judgment in any decision-making process. The Canadian Agency f or Drugs and
Technologies in Health (CADTH) does not endorse any inf ormation, drugs, therapies, treatments, products, processes, or serv ic es.
While care has been taken to ensure that the inf ormation prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date
the material was f irst published by CADTH, CADTH does not make any guarantees to that ef f ect. CADTH does not guarantee and is not responsible f or the
quality , currency , propriety , accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing
this document. The v iews and opinions of third parties published in this document do not necessarily state or ref lect those of CADTH.
CADTH is not responsible f or any errors, omissions, injury , loss, or damage arising f rom or relating to the use (or misuse) of any inf ormation, statements, or
conclusions contained in or implied by the contents of this document or any of the source materials.
This document may contain links to third-party websites. CADTH does not hav e control ov er the content of such sites. Use of third-party sites is gov erned by
the third-party website owners’ own terms and conditions set out f or such sites. CADTH does not make any guarantee with respect to any inf ormation
contained on such third-party sites and CADTH is not responsible f or any injury , loss, or damage suf f ered as a result of using such third-party sites. CADTH
has no responsibility f or the collection, use, and disclosure of personal inf ormation by third-party sites.
Subject to the af orementioned limitations, the v iews expressed herein are those of CADTH and do not necessarily represent the v iews of Canada’s f ederal,
prov incial, or territorial gov ernments or any third party supplier of inf ormation.
This document is prepared and intended f or use in the context of the Canadian health care sy stem. The use of this document outside of Canada is done so at
the user’s own risk.
This disclaimer and any questions or matters of any nature arising f rom or relating to the content or use (or misuse) of this document will be gov erned by and
interpreted in accordance with the laws of the Prov ince of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the
exclusiv e jurisdiction of the courts of the Prov ince of Ontario, Canada.
The copy right and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian
Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document f or non-commercial purposes
only , prov ided it is not modif ied when reproduced and appropriate credit is giv en to CADTH and its licensors.
About CADTH: CADTH is an independent, not-f or-prof it organization responsible f or prov iding Canada’s health care decision-makers with objectiv e ev idence
to help make inf ormed decisions about the optimal use of drugs, medical dev ices, diagnostics, and procedures in our health care sy stem.
Funding: CADTH receiv es f unding f rom Canada’s f ederal, prov incial, and territorial gov ernments, with the exception of Quebec.
SUMMARY OF ABSTRACTS Transcutaneous Bilirubin Measurements in Newborns 3
Research Questions
1. What is the clinical effectiveness and diagnostic accuracy of transcutaneous bilirubin measurements in newborns?
2. What is the cost-effectiveness of transcutaneous bilirubin measurements in newborns compared with serum bilirubin measurements?
3. What are the evidence-based guidelines regarding transcutaneous bilirubin measurements in newborns?
Key Findings
One health technology assessment report, one systematic review with meta-analysis, one
randomized controlled trial, 21 non-randomized studies, and one economic evaluation were
identified regarding the clinical effectiveness, diagnostic accuracy, or cost-effectiveness of
transcutaneous bilirubin measurements in well newborns. Additionally, three evidence-
based guidelines were identified.
Methods
A limited literature search was conducted on key resources including PubMed, The
Cochrane Library, University of York Centre for Reviews and Dissemination (CRD)
databases and a focused Internet search. No methodological filters were applied to limit
retrieval by publication type. The search was limited to English language documents
published between November 1, 2013 and November 7, 2017.
Selection Criteria
One reviewer screened citations and selected studies based on the inclusion criteria
presented in Table 1.
Table 1: Selection Criteria
Population Well newborns (under 10 days of age), in hospital
Intervention Transcutaneous devices for measuring bilirubin (e.g., Philips BiliChek, Minolta Jaundice Meter , Drager JM-03)
Comparator Q1-Q2: Serum bilirubin measurements Q3: No comparator required
Outcomes Q1: Clinical effectiveness; Diagnostic accuracy (i.e., sensitivity and specificity) Q2: Cost-effectiveness Q3: Evidence-based guidelines
Study Designs Health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, non-randomized studies, economic evaluations, evidence-based guidelines
SUMMARY OF ABSTRACTS Transcutaneous Bilirubin Measurements in Newborns 4
Results
Rapid Response reports are organized so that the higher quality evidence is presented first.
Therefore, health technology assessment reports, systematic reviews, and meta-analyses
are presented first. These are followed by randomized controlled trials , non-randomized
studies, economic evaluations, and evidence-based guidelines.
One health technology assessment report, one systematic review with meta-analysis, one
randomized controlled trial, 21 non-randomized studies, and one economic evaluation were
identified regarding the clinical effectiveness, diagnostic accuracy, or cost-effectiveness of
transcutaneous bilirubin measurements in well newborns. Additionally, three evidence-
based guidelines were identified.
Additional references of potential interest are provided in the appendix.
Overall Summary of Findings
One health technology assessment (HTA) report,1 one systematic review (SR) with meta-
analysis,2 one randomized controlled trial (RCT),
3 21 non-randomized studies (NRS),
4-24
and one economic evaluation25
were identified regarding the clinical effectiveness,
diagnostic accuracy, or cost-effectiveness of transcutaneous bilirubin (TcB) measurements
in well newborns. Detailed study characteristics are provided in Table 2.
The identified HTA1 concluded that although TcB devices can safely predict neonatal
hyperbilirubinemia they cannot be used as a replacement for total serum bilirubin
measurements (TSB). The SR with meta-analysis2 revealed no significant differences
between TcB and TSB nomograms, suggesting either can be used to identify subsequent
significant hyperbilirubinemia. The conclusions made by the authors of the 23 individual
studies varied greatly.3-25
Fifteen of these studies suggested TcB measurements were well
correlated to serum bilirubin measurements or provided clinical benefit,3,5,7-11,14-19,23
while
seven studies concluded TcB tended to overestimate or underestimate serum bilirubin,
resulting in low levels of correlation.4,6,12,13,21-22,24
Three evidence-based guidelines26-28
were identified regarding transcutaneous bilirubin
measurements in well newborns. One guideline,28
published by the National Institute for
Health and Care Excellence, recommends measuring transcutaneous bilirubin in babies
(gestational age ≥ 35 weeks) who are over 24 hours old. If the transcutaneous
bilirubinometer measurement indicates a bilirubin level greater than 250 micromol/litre, the
guideline recommends measuring the serum bilirubin to check the result and to guide
treatment decisions. The second guideline27
was an update by Wan et al., approved by the
Ministry of Health Malaysia in 2014, to a previous publication. This guideline states that
transcutaneous bilirubinometers may be used in the assessment of neonatal jaundice. This
guideline also contained information on the treatment and prevention of neonatal jaundice.
Finally, the third guideline28
by Wilkinson et al. made a “weak recommendation” to support
screening for hyperbilirubinemia in newborn infants using transcutaneous bilirubin
measurement, early serum bilirubin measurement, or a combination of these methods to
prevent severe complications.
SUMMARY OF ABSTRACTS Transcutaneous Bilirubin Measurements in Newborns 5
Table 2: Summary of Included Studies on the Clinical Effectiveness, Diagnostic Accuracy,
or Cost-effectiveness of Transcutaneous Bilirubin Measurements in Well Newborns
First Author, Year
Study Characteristics
Intervention Comparator Outcomes Conclusions
Health Technology Assessments
Institute of Health Economics, 2013
1
39 primary studies included
SR and critical appraisal conducted
Economic analysis performed
TcB screening
TSB
Visual assessment
Comparison between TcB devices
Diagnostic accuracy
Procedure-related adverse events
Incidence of significant neonatal hyperbilirubinemia
Cost-effectiveness
The BiliCheck and JM-103 devices provided a rapid, non-invasive, point-of-care test for predicting neonatal hyperbilirubinemia that appeared to be safe
TcB screening cannot replace TSB due to the potential for both overestimation and underestimation of TSB values
TcB was useful as a valid screening tool to determine the need for a confirmatory TSB test
The cost-effectiveness of TcB screening was uncertain
Systematic Reviews and Meta-Analyses
Yu, 20142
MA performed
14 studies included
N=NR
TcB nomograms
TSB nomograms
Predictive value for significant hyperbilirubinemia
MA revealed no difference in the predictive abilities of TcB and TSB nomograms
The authors stated that this result should be taken with caution due to methodological limitations of the studies included in this SR
Randomized Controlled Trials
van den Esker-Jonker, 2016
3 Hospitalized
jaundiced neonates (gestational age ≥ 32 weeks)
N=430
TcB to determine need for TSB
Visual and clinical assessment to determine need for TSB
Number of blood samples before phototherapy
Peak of bilirubin value
Indications for phototherapy
Exchange transfusion
Length of hospitalization
The number of blood draws was significantly reduced (by 38.5%) in the TcB group
There were no significant differences in other outcomes of interest between groups
The authors concluded TcB was safe, feasible, and resulted in a decrease in the number of blood draws
SUMMARY OF ABSTRACTS Transcutaneous Bilirubin Measurements in Newborns 6
First Author, Year
Study Characteristics
Intervention Comparator Outcomes Conclusions
Non-Randomized Studies
Fine, 20174
Preterm and term infants
N=NR
TcB measurement
TSB measurement
Sensitivity and specificity of TcB
“Median TcB b ias was 2.6 and 2.5 mg dl
-1 for term
and preterm infants in the
first 3 days of life, respectively. However, median b ias was 2.2 mg dl
-
1 for preterm infants at 4 to
7 days of life. TcB in
preterm infants predicted high-intermediate or high-risk TSB with 94% sensitivity and 56% specificity. TcB screening protocols developed for term infants can be used for late preterm infants in the first 3 days of life.”
4
Jain, 20175
Healthy, term, appropriate for gestational age neonates
N=500
TcB at 24 and 48 hours of age
TSB at 72 hours of age
Sensitivity
Specificity Predictive values
TcB cut-off values of 7 mg/dL at 24 hours and 10 mg/dL at 48 hours were identified as the most effective in predicting subsequent hyperbilirubinemia
The authors concluded 24 hour and 48 hour TcB values were good predictors of subsequent hyperbilirubinemia (24 hour value had stronger predictive ability)
Jones, 20176
Newborns
N=178
TcB measurement (with JM-105 and BiliChek devices)
TSB measurement
TcB/TSB correlation
The highest TcB/TSB correlation with the JM-105 device was achieved on the sternum, with an overall correlation value of 0.93
TcB accuracy varied among races
In 5% of measurements, TcB with JM-105 on the sternum underestimated TSB by ≥2 mg/dL
Nahar, 20177
Late preterm and term newborns (gestational age ≥ 35 weeks)
N=160
TcB measurement
TSB measurement
Mean difference of TcB and TSB
Sensitivity Specificity
Accuracy
A sensitivity of 77%, specificity of 88%, and accuracy of 82% were obtained using a TcB cut off value of 15 mg/dl
The authors concluded TcB can reduce the
SUMMARY OF ABSTRACTS Transcutaneous Bilirubin Measurements in Newborns 7
First Author, Year
Study Characteristics
Intervention Comparator Outcomes Conclusions
need for TSB in neonates
Olusanya, 2017
8 Infants with
paired TcB and TSB measurements
N=1,011
TcB measurement
TSB measurement
Predictive performance of TcB
TcB demonstrated NPVs of 99.0-99.9% and PPVs of 7.7-15.5% across all criteria
TcB was effective in identifying infants that do not require phototherapy. However, it may identify a high proportion of false positives
Yamana, 20179
Japanese newborns (gestational age ≥ 35 weeks)
N=82
TcB measurement (with BiliCare system)
TSB measurement
TcB measurement (with JM-105)
TcB/TSB correlation
Mean difference of TcB and TSB
TcB significantly correlated with TSB
TcB measured at the scaphoid fossa or conchal cavity were more reliable than those at the earlobe
Alsaedi, 201610
Healthy, jaundiced Saudi term newborns
N=665
TcB measurement
TSB measurement
TcB/TSB correlation
Sensitivity
Specificity PPV
NPV
TcB sensitivity and specificity to predict TSB during the first 72 hours of life were estimated at 83% and 71%, respectively
A PPV of 63% and a NPV of 87% were reported
The authors concluded TcB measurement provided accurate estimates of TSB values
Kitsommart, 2016
11 Healthy late
preterm and term infants
N=114 paired samples (from 93 infants)
TcB measurement(with BiliCare system)
TSB measurement
Mean difference of TcB and TSB
Sensitivity
NPV
“The BiliCare(TM) demonstrated good performance with positive b ias for the screening of jaundice in healthy late preterm or term infants. However, if adopted, proper cut-off levels should be chosen because of sub -optimal device precision.”
11
Olusanya, 2016
12 Black African
neonates N=2,107 paired
samples (from 1,553 infants)
TcB measurement (with JM-105 and BiliChek devices)
TSB measurement
Divergence between TcB and TSB values
Both the BiliChek and the JM-103 devices overestimate TSB in black African neonates, which may result in unnecessary treatments
JM-103 device was associated with higher
SUMMARY OF ABSTRACTS Transcutaneous Bilirubin Measurements in Newborns 8
First Author, Year
Study Characteristics
Intervention Comparator Outcomes Conclusions
levels of overestimation than the BiliChek device
Pratesi, 201613
Late preterm and term Caucasian infants with non-hemolytic jaundice (gestational age ≥ 35 weeks)
N=458
TcB measurement (with BiliCare)
TcB measurement (with JM-105)
TSB measurement
Mean difference of TcB between devices
TcB measurements with both devices were well correlated
BiliCare tended to over-estimate TsB for mild and moderate values and under-estimate it for high values compared to JM-103
Comparison between TcB and TSB were not made in the abstract
Afjeh, 201514
Neonates weighing ≥ 1,800 g (gestational age ≥ 35 weeks)
N=613
TcB measurement
TSB measurement
TcB/TSB correlation
PPV
TcB demonstrated a PPV of 81% for the diagnosis of hyperbilirubinemia
A correlation coefficient of 72% was observed between TcB and TSB
Authors highly recommended TcB to be performed routinely due to high incidence of hyperbilirubinemia in neonates
Mahram, 2015
15 Neonates
admitted to hospital because of neonatal indirect jaundice
N=256
TcB measurement (with KJ-8000 device)
TSB measurement
TcB/TSB correlation
Sensitivity
Specificity
TcB/TSB correlation was observed to be 0.82
Sensitivity and specificity were found to be 0.844 and 0.842, respectively
The authors concluded that TcB can be used as a reliable tool to bilirubin in neonates
Taylor, 201516
Neonates admitted to participating newborn nurseries
N=8,319
TcB measurement
TSB measurement
Mean difference of TcB and TSB
TcB/TSB correlation
The mean difference between TcB and TSB values was 0.84 mg/dL
Mean difference between TcB and TSB values was higher in African-American newborns
The correlation between paired TcB/TSB measurements was 0.78
The authors concluded that Tcb measurement provided a reasonable estimate of TSB levels in
SUMMARY OF ABSTRACTS Transcutaneous Bilirubin Measurements in Newborns 9
First Author, Year
Study Characteristics
Intervention Comparator Outcomes Conclusions
healthy newborns
Afanetti, 201417
Preterm and term infants
N=85
TcB measurement (with Draeger JM-103(R) device)
TSB measurement
Correlation and agreement between TcB and TSB values
“TcB measurements using the Draeger JM-103(R) device correlate
significantly with TSB, regardless of term and skin color. Transcutaneous b ilirubinometry seems to be a safe and cost-effective
screening method for severe hyperb ilirubinemia in newborns of different terms and ethnic origins.”
17
Conceicao, 2014
18 Term newborns
with no hemolytic disease
N=58
TcB measurement (performed on the forehead or sternum with Bilicheck(R) device)
TSB measurement
Correlation and agreement between TcB and TSB values
TcB measurement on the sternum was more effective than when measured on the forehead
Mean TcB values measured on the sternum corresponded well with TSB values
Mazur, 201419
Low-risk newborn infants with normal bilirubin levels N=34
TcB measurement (with JM103 device)
TSB measurement
Differences and limits of agreement between sequential measurements
“We found good agreement between TcB measurements obtained sequentially by a single user and by two different users of the device, as well as between laboratory TSB values in low-risk newborn infants with normal b ilirubin levels. These findings support the use of a noninvasive b ilirubin meter to screen for hyperb ilirubinemia, which
could reduce the amount of b lood obtained invasively from newborns”
19
Mohamed, 2014
20 Healthy term
and near-term newborns
N=141
Plotting TcB values on a transcutaneous nomograms (Fouzas et al. and Maisels and Kring)
Plotting TcB values on a TSB nomogram
Plotting TSB values on a TSB nomogram (Bhutani et al.)
Risk of developing significant hyperbilirubinemia
False negative rate Sensitivity
Specificity
PPV and NPV
Plotting TcB values on a TSB nomogram was associated with higher false negative rate and decreased predictive characteristics
SUMMARY OF ABSTRACTS Transcutaneous Bilirubin Measurements in Newborns 10
First Author, Year
Study Characteristics
Intervention Comparator Outcomes Conclusions
(Bhutani et al.)
Neocleous, 2014
21 Clinically
jaundiced healthy-term Greek newborns
N=368 paired samples (from 222 infants)
TcB measurement (with BiliCheck device)
TSB measurement
Level of agreement between TcB and TSB values
TcB and TSB values did not correlate well
TcB tended to overestimate TSB with wide 95% limits of agreement
Rylance, 2014
22 Jaundiced
newborn infants
N=128
TcB measurement (from forehead and sternum)
TSB measurement
Correlation and agreement between TcB and TSB values
Sensitivity Specificity
TcB values tended to overestimate the degree of jaundice
A sensitivity of 91% and a specificity of 90% were observed in infants not undergoing phototherapy
For infants undergoing phototherapy, TcB had good sensitivity (94%), but lower specificity (36%)
The authors concluded TcB can be used to safely guide phototherapy in a resource-poor setting
Samiee-Zafarghandy, 2014
23
Newborns of various skin colours
N=451
TcB measurement (with JM103 device)
TSB measurement
Association between TcB and TSB values
TcB underestimated TSB in light and medium skin colours infants and overestimated TSB in dark skin colour
The authors concluded that the JM103 device was a useful screening tool to identify infants in need of TSB, regardless of their skin colour
Simsek, 201424
Healthy Turkish neonates (gestational age ≥ 36 weeks)
N=250
TcB measurement (with JM103 device)
TSB measurement
Correlation between TcB and TSB values
Mean difference of TcB and TSB
TcB tended to underestimate TSB, with a larger discrepancy at higher TSB values
The mean difference of TcB and TSB was lower in infants not requiring phototherapy than infants that required phototherapy
The JM-103 device is a suitable screening tool to identify jaundiced infants
SUMMARY OF ABSTRACTS Transcutaneous Bilirubin Measurements in Newborns 11
First Author, Year
Study Characteristics
Intervention Comparator Outcomes Conclusions
and it may reduce the need for TSB measurements
Economic Evaluations
Srinivas, 2016
25 Neonates
admitted only to the Level 1 nursery (gestational age ≥ 37 weeks)
N=552
TcB measurement (with BiliChek(R) meter)
TSB measurement
Correlation between TcB and TSB values
NPV
Potential cost savings
Correlation between TcB and TSB was estimated at 0.69
A NPV of 99.4% was reported
TcB use was associated with a potential cost savings of $1500.00 per 100 patients
The authors concluded TcB can used as a stand-alone test until values are close to phototherapy threshold
MA = meta-analy sis; NPV = negativ e predictiv e v alue; NR = not reported; PPV = positiv e predictiv e v alue; TcB: transcutaneous bilirubin; TSB = total serum bilirubin; RCT
= randomized controlled trial; SR = sy stematic rev iew.
References Summarized
Health Technology Assessments
1. Transcutaneous bilirubinometry for the screening of neonatal hyperbilirubinemia
[Internet]. Edmonton (AB): Institute of Health Economics; 2013 April 03. [cited 2017 Nov
20]. Available from: https://www.ihe.ca/publications/transcutaneous-bilirubinometry-for-
the-screening-of-neonatal-hyperbilirubinemia
Systematic Reviews and Meta-Analyses
2. Yu ZB, Han SP, Chen C. Bilirubin nomograms for identification of neonatal
hyperbilirubinemia in healthy term and late-preterm infants: a systematic review and
meta-analysis. World J Pediatr. 2014 Aug;10(3):211-8.
PubMed: PM25124971
Randomized Controlled Trials
3. van den Esker-Jonker B, den Boer L, Pepping RM, Bekhof J. Transcutaneous
bilirubinometry in jaundiced neonates: a randomized controlled trial. Pediatrics. 2016
Dec;138(6).
PubMed: PM27940715
https://www.ihe.ca/publications/transcutaneous-bilirubinometry-for-the-screening-of-neonatal-hyperbilirubinemiahttps://www.ihe.ca/publications/transcutaneous-bilirubinometry-for-the-screening-of-neonatal-hyperbilirubinemiahttp://www.ncbi.nlm.nih.gov/pubmed/25124971http://www.ncbi.nlm.nih.gov/pubmed/27940715
SUMMARY OF ABSTRACTS Transcutaneous Bilirubin Measurements in Newborns 12
Non-Randomized Studies
4. Fine KL, Carey WA, Schuster JAW, Bryant SC, Cook WJ, Karon BS. Defining the
limitations of transcutaneous bilirubin measurement in late preterm newborns. J
Perinatol. 2017 Jun;37(6):658-61.
PubMed: PM28206994
5. Jain M, Bang A, Tiwari A, Jain S. Prediction of significant hyperbilirubinemia in term
neonates by early non-invasive bilirubin measurement. World J Pediatr. 2017
Jun;13(3):222-7.
PubMed: PM27878783
6. Jones DF, McRea AR, Knowles JD, Lin FC, Burnette E, Reller LA, et al. A prospective
comparison of transcutaneous and serum bilirubin within brief time intervals. Clin
Pediatr (Phila). 2017 Oct;56(11):1013-7.
PubMed: PM28366015
7. Nahar N, Mannan MA, Dey AC, Ahmed F, Khan KA, Jahan I, et al. Comparison of
serum bilirubin with transcutaneous bilirubinometry in late preterm and term newborn.
Mymensingh Med J. 2017 Jul;26(3):621-7.
PubMed: PM28919619
8. Olusanya BO, Emokpae AA. Use of transcutaneous bilirubin to determine the need for
phototherapy in resource-limited settings. Neonatology. 2017;111(4):324-30.
PubMed: PM28073104
9. Yamana K, Morioka I, Kurokawa D, Fukushima S, Nishida K, Ohyama S, et al.
Evaluation of BiliCare transcutaneous bilirubin device in Japanese newborns. Pediatr
Int. 2017 Oct;59(10):1058-63.
PubMed: PM28703875
10. Alsaedi SA. Transcutaneous bilirubin measurement in healthy Saudi term newborns
[Internet]. Saudi Med J. 2016 Feb [cited 2017 Nov 20];37(2):142-6. Available from:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800911
PubMed: PM26837395
11. Kitsommart R, Yangthara B, Wutthigate P, Paes B. Accuracy of transcutaneous bilirubin
measured by the BiliCare device in late preterm and term neonates. J Matern Fetal
Neonatal Med. 2016 Nov;29(22):3641-5.
PubMed: PM26762721
12. Olusanya BO, Imosemi DO, Emokpae AA. Differences between transcutaneous and
serum bilirubin measurements in Black African neonates. Pediatrics. 2016 Sep;138(3).
PubMed: PM27577578
13. Pratesi S, Boni L, Tofani L, Berti E, Sollai S, Dani C. Comparison of the transcutaneous
bilirubinometers BiliCare and Minolta JM-103 in late preterm and term neonates. J
Matern Fetal Neonatal Med. 2016 Sep;29(18):3014-8.
PubMed: PM26632858
http://www.ncbi.nlm.nih.gov/pubmed/28206994http://www.ncbi.nlm.nih.gov/pubmed/27878783http://www.ncbi.nlm.nih.gov/pubmed/28366015http://www.ncbi.nlm.nih.gov/pubmed/28919619http://www.ncbi.nlm.nih.gov/pubmed/28073104http://www.ncbi.nlm.nih.gov/pubmed/28703875http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800911http://www.ncbi.nlm.nih.gov/pubmed/26837395http://www.ncbi.nlm.nih.gov/pubmed/26762721http://www.ncbi.nlm.nih.gov/pubmed/27577578http://www.ncbi.nlm.nih.gov/pubmed/26632858
SUMMARY OF ABSTRACTS Transcutaneous Bilirubin Measurements in Newborns 13
14. Afjeh A, Fallahi M, Jahanbeen M, Basiri A, Allaee M. Pre-discharge screening trans-
cutaneous bilirubinometry in healthy newborns in Mahdieh Hospital, Tehran. Iran J
Pediatr. 2015 Aug;25(4):e2187. Available from:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575797
PubMed: PM26396699
15. Jackson GL, Saumur M, Chandwani V, Engle WD. Evaluation of early transcutaneous
bilirubinometry to predict subsequent hyperbilirubinemia in neonates admitted to a well-
baby nursery. Am J Perinatol. 2015 Aug;32(10):944-51.
PubMed: PM25738788
16. Mahram M, Oveisi S, Jaberi N. Trans-cutaneous bilirubinometery versus serum bilirubin
in neonatal jaundice. Acta Med Iran. 2015 Dec;53(12):764-9.
PubMed: PM26749233
17. Taylor JA, Burgos AE, Flaherman V, Chung EK, Simpson EA, Goyal NK, et al.
Discrepancies between transcutaneous and serum bilirubin measurements. Pediatrics
[Internet]. 2015 Feb [cited 2017 Nov 20];135(2):224-31. Available from:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306797
PubMed: PM25601981
18. Afanetti M, Eleni Dit TS, Yousef N, Jrad I, Mokhtari M. Transcutaneous bilirubinometry
is not influenced by term or skin color in neonates. Early Hum Dev. 2014 Aug;90(8):417-
20.
PubMed: PM24951079
19. Conceicao CM, Dornaus MF, Portella MA, Deutsch AD, Rebello CM. Influence of
assessment site in measuring transcutaneous bilirubin. Einstein (Sao Paulo) [Internet].
2014 Jan [cited 2017 Nov 20];12(1):11-5. Available from:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898232
PubMed: PM24728239
20. Mazur MG, Mihalko-Mueller J, Callans H, Klesh D, Sell H, Bendig D. Reproducability of
non-invasive bilirubin measurements. MCN Am J Matern Child Nurs. 2014
Jul;39(4):225-30.
PubMed: PM24978001
21. Mohamed I, Blanchard AC, Delvin E, Cousineau J, Carceller A. Plotting transcutaneous
bilirubin measurements on specific transcutaneous nomogram results in better
prediction of significant hyperbilirubinemia in healthy term and near-term newborns: a
pilot study. Neonatology. 2014;105(4):306-11.
PubMed: PM24603449
22. Neocleous C, Adramerina A, Limnaios S, Symeonidis S, Spanou C, Malakozi M, et al. A
comparison between transcutaneous and total s erum bilirubin in healthy-term Greek
neonates with clinical jaundice. Prague Med Rep. 2014;115(1-2):33-42.
PubMed: PM24874933
23. Rylance S, Yan J, Molyneux E. Can transcutaneous bilirubinometry safely guide
phototherapy treatment of neonatal jaundice in Malawi? Paediatr Int Child Health. 2014
May;34(2):101-7.
PubMed: PM24090969
http://www.ncbi.nlm.nih.gov/pubmed/26396699http://www.ncbi.nlm.nih.gov/pubmed/25738788http://www.ncbi.nlm.nih.gov/pubmed/26749233http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306797http://www.ncbi.nlm.nih.gov/pubmed/25601981http://www.ncbi.nlm.nih.gov/pubmed/24951079http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898232http://www.ncbi.nlm.nih.gov/pubmed/24728239http://www.ncbi.nlm.nih.gov/pubmed/24978001http://www.ncbi.nlm.nih.gov/pubmed/24603449http://www.ncbi.nlm.nih.gov/pubmed/24874933http://www.ncbi.nlm.nih.gov/pubmed/24090969
SUMMARY OF ABSTRACTS Transcutaneous Bilirubin Measurements in Newborns 14
24. Samiee-Zafarghandy S, Feberova J, Williams K, Yasseen AS, Perkins SL, Lemyre B.
Influence of skin colour on diagnostic accuracy of the jaundice meter JM 103 in
newborns. Arch Dis Child Fetal Neonatal Ed. 2014 Nov;99(6):F480-F484.
PubMed: PM25074981
25. Simsek FM, Narter F, Erguven M. Comparison of transcutaneous and total serum
bilirubin measurement in Turkish newborns. Turk J Pediatr. 2014 Nov;56(6):612-7.
PubMed: PM26388591
Economic Evaluations
26. Srinivas GL, Cuff CD, Ebeling MD, Mcelligott JT. Transcutaneous bilirubinometry is a
reliably conservative method of assessing neonatal jaundice. J Matern Fetal Neonatal
Med. 2016;29(16):2635-9.
PubMed: PM26483074
Guidelines and Recommendations
27. Jaundice in newborn babies under 28 days [Internet]. London: National Institute for
Health Care and Excellence (NICE); 2016 Oct. [cited 2017 Nov 20]. (Clinical guideline;
no. 98). Available from: https://www.nice.org.uk/guidance/cg98
See: Transcutaneous b ilirubin screening and risk factors, page 22
28. Wan A, Mat DS, Teh SH, Choo YM, Kutty FM. Management of neonatal jaundice in
primary care. Malays Fam Physician [Internet]. 2016 [cited 2017 Nov 20];11(2-3):16-9.
Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408871
PubMed: PM28461853
29. Wilkinson J, Bass C, Diem S, Gravley A, Harvey L, Maciosek M, et al. Health care
guideline: preventive services for children and adolescents [Internet]. Bloomington
(MN): Institute for Clinical Systems Improvement; 2013 Sept. Available from:
http://www.doc4teens.com/support-files/adolescent-preventative-services.pdf
See: 23. Hyperb ilirubinemia Screening, page 38
http://www.ncbi.nlm.nih.gov/pubmed/25074981http://www.ncbi.nlm.nih.gov/pubmed/26388591http://www.ncbi.nlm.nih.gov/pubmed/26483074https://www.nice.org.uk/guidance/cg98http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408871http://www.ncbi.nlm.nih.gov/pubmed/28461853http://www.doc4teens.com/support-files/adolescent-preventative-services.pdf
SUMMARY OF ABSTRACTS Transcutaneous Bilirubin Measurements in Newborns 15
Appendix — Further Information
Previous CADTH Reports
30. Transcutaneous bilirubin measurements in newborns: clinical and cost-effectiveness,
and guidelines [Internet]. Ottawa: CADTH; 2013 Dec 9 [cited 2017 Nov 20]. (CADTH
rapid response report: summary of abstracts). Available from:
https://www.cadth.ca/transcutaneous-bilirubin-measurements-newborns-clinical-and-
cost-effectiveness-and-guidelines
Systematic Reviews and Meta-Analyses
Alternative Population – Newborns Receiving Phototherapy
31. Nagar G, Vandermeer B, Campbell S, Kumar M. Effect of phototherapy on the reliability
of transcutaneous bilirubin devices in term and near-term infants: a systematic review
and meta-analysis. Neonatology. 2016;109(3):203-12.
PubMed: PM26789390
Alternative Population – Preterm Infants
32. Nagar G, Vandermeer B, Campbell S, Kumar M. Reliability of transcutaneous bilirubin
devices in preterm infants: a systematic review. Pediatrics. 2013 Nov;132(5):871-81.
PubMed: PM24127472
Non-Randomized Studies
Alternative Population – Newborns Receiving Phototherapy
33. Katayama Y, Enomoto M, Kikuchi S, Takei A, Ikegami H, Minami H, et al.
Transcutaneous bilirubin measurement during phototherapy in term neonates. Pediatr
Int. 2017 Jun;59(6):686-90.
PubMed: PM28118513
34. Murli L, Thukral A, Sankar MJ, Vishnubhatla S, Deorari AK, Paul VK, et al. Reliability of
transcutaneous bilirubinometry from shielded skin in neonates receiving phototherapy: a
prospective cohort study. J Perinatol. 2017 Feb;37(2):182-7.
PubMed: PM27763628
35. Casnocha LL, Matasova K, Zibolen M, Krcho P. Accuracy of transcutaneous b ilirubin
measurement in newborns after phototherapy. J Perinatol. 2016 Oct;36(10):858-61.
PubMed: PM27279078
36. Radfar M, Hashemieh M, Shirvani F, Madani R. Transcutaneous bilirubinometry in
preterm and term newborn infants before and during phototherapy. Arch Iran Med. 2016
May;19(5):323-8.
PubMed: PM27179163
37. Grabenhenrich J, Grabenhenrich L, Buhrer C, Berns M. Transcutaneous bilirub in after
phototherapy in term and preterm infants. Pediatrics. 2014 Nov;134(5):e1324-e1329.
PubMed: PM25332501
https://www.cadth.ca/transcutaneous-bilirubin-measurements-newborns-clinical-and-cost-effectiveness-and-guidelineshttps://www.cadth.ca/transcutaneous-bilirubin-measurements-newborns-clinical-and-cost-effectiveness-and-guidelineshttp://www.ncbi.nlm.nih.gov/pubmed/26789390http://www.ncbi.nlm.nih.gov/pubmed/24127472http://www.ncbi.nlm.nih.gov/pubmed/28118513http://www.ncbi.nlm.nih.gov/pubmed/27763628http://www.ncbi.nlm.nih.gov/pubmed/27279078http://www.ncbi.nlm.nih.gov/pubmed/27179163http://www.ncbi.nlm.nih.gov/pubmed/25332501
SUMMARY OF ABSTRACTS Transcutaneous Bilirubin Measurements in Newborns 16
38. Juster-Reicher A, Flidel-Rimon O, Rozin I, Shinwell ES. Correlation of transcutaneous
bilirubinometry (Tcb) and total serum bilirubin (TsB) levels after phototherapy. J Matern
Fetal Neonatal Med. 2014 Sep 30;1-3.
PubMed: PM25234102
Clinical Practice Guidelines – Uncertain Methodology
39. Jaundice and hyperbilirubinemia in the newborn: assessment and management
[Internet]. Winnipeg (MB): Winnipeg Regional Health Authority, 2017 Jan [cited 2017
Nov 20]. Available from: http://www.wrha.mb.ca/extranet/eipt/files/EIPT-035-024.pdf
40. Guidelines for detection, management and prevention of hyperbilirubinemia in term and
late preterm newborn infants [Internet]. Toronto: Canadian Paediatric Society; 2016 Feb
1 [cited 2017 Nov 20]. Available from:
https://www.cps.ca/en/documents/position/hyperbilirubinemia-newborn
41. Queensland maternity and neonatal guideline: neonatal jaundice [Internet]. Brisbane
(AU): Queensland Health; 2012 Nov [cited 2017 Nov 20]. Available from:
https://www.health.qld.gov.au/__data/assets/pdf_file/0018/142038/g_jaundice.pdf
Review Articles
42. Bhardwaj K, Locke T, Biringer A, Booth A, Darling EK, Dougan S, et al. Newborn
bilirubin screening for preventing severe hyperbilirubinemia and bilirubin
encephalopathy: a rapid review. Curr Pediatr Rev. 2017;13(1):67-90.
PubMed: PM28071585
43. Maisels MJ. Transcutaneous bilirubin measurement: does it work in the real world?
Pediatrics. 2015 Feb;135(2):364-6.
PubMed: PM25601975
44. Engle WD, Jackson GL, Engle NG. Transcutaneous bilirubinometry. Semin Perinatol.
2014 Nov;38(7):438-51.
PubMed: PM25282473
45. Muchowski KE. Evaluation and treatment of neonatal hyperbilirubinemia. Am Fam
Physician. 2014 Jun 1;89(11):873-8.
PubMed: PM25077393
http://www.ncbi.nlm.nih.gov/pubmed/25234102http://www.wrha.mb.ca/extranet/eipt/files/EIPT-035-024.pdfhttps://www.cps.ca/en/documents/position/hyperbilirubinemia-newbornhttps://www.health.qld.gov.au/__data/assets/pdf_file/0018/142038/g_jaundice.pdfhttp://www.ncbi.nlm.nih.gov/pubmed/28071585http://www.ncbi.nlm.nih.gov/pubmed/25601975http://www.ncbi.nlm.nih.gov/pubmed/25282473http://www.ncbi.nlm.nih.gov/pubmed/25077393